On Wednesday, U.S. District Judge Matthew Kennelly invalidated Pfizer’s patents related to the cancer drug Nerlynx, overturning a jury's $107.5 million award against AstraZeneca. Pfizer had claimed AstraZeneca's Tagrisso infringed these patents. Judge Kennelly's ruling found the patents lacked sufficient written descriptions and were not reproducible by a skilled scientist. This decision dismisses the damages awarded in May and affects Pfizer’s ongoing patent infringement claims. The case, Wyeth LLC v. AstraZeneca Pharmaceuticals LP, was heard in the District of Delaware. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
